Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 2,872 $ 1,577
General and administrative 1,333 1,161
Total operating expenses 4,205 2,738
Loss from operations (4,205) (2,738)
Other (expense) income:    
Interest expense, net (1) (1)
Foreign exchange loss (13)
Change in fair value of derivative liabilities 11 1
Total other expense, net (3)
Net loss $ (4,208) $ (2,738)
Net loss per common share, basic and diluted $ (0.04) $ (0.04)
Weighted average number of common shares outstanding, basic and diluted 97,469 71,248